Protein Kinase Cι (PKCι) is an atypical PKC isoform and participates in multiple aspects of the transformed phenotype in human cancer cells. We previously reported that frequent amplification and overexpression of PKCι were correlated with lymph node metastasis in primary esophageal squamous cell carcinomas (ESCC). In the present study, siRNA-mediated silencing of PKCι revealed that this enzyme was required for cell migration, invasion, and 
Introduction
Esophageal squamous cell carcinoma (ESCC) is one of the most common human malignancies. The prognosis of ESCC patients has not significantly improved, with an average five year survival rate of 10%-20% (1) . Therefore, exploring the mechanisms involved in the development and progression of this disease is the key to effective treatment.
The protein kinase C (PKC) family consists of at least 12 distinct lipid-regulated protein-serine/threonine kinases that are involved in multiple intracellular pathways and play pivotal roles in regulating cell proliferation, differentiation and survival (2) . The PKC isoenzymes are subdivided into three main classes: the cPKCs (conventional PKCs; PKCα, βI, βII and γ), the nPKCs (novel PKCs; PKCδ, ε, η and θ) and the aPKCs (atypical PKCs; PKCζ and ι/λ). Atypical protein kinase C type ι (PKCι) has been implicated in the establishment of cell polarity and cell survival (3) . PKCι activity can be regulated by PI3K through PDK1 phosphorylation (4) and protein-protein interactions with upstream effectors, such as Ras (5) .
PKCι is reported to be amplified and overexpressed in several human cancers, and its overexpression is correlated with poor prognosis in lung, ovarian and pancreatic cancer (6) (7) (8) (9) (10) .
We recently demonstrated that PKCι was frequently amplified and overexpressed in primary ESCC tumors. Moreover, the amplification and overexpression of PKCι were correlated with lymph node metastasis, which indicates that PKCι might play a role in ESCC progression (9) .
However, the molecular mechanisms underlying the role of PKCι in ESCC remain unclear.
S phase kinase-associated protein 2 (SKP2) acts as a substrate-specific factor for the Skp1-Cul1-F-box (SCF) complex that regulates the destruction of multiple important proteins, including p27, p21, Rb, and p53 (11) (12) (13) . Elevated SKP2 expression is frequently observed in (14, 15) . Our recent investigation revealed that SKP2 was amplified and overexpressed in primary ESCC tumors (16) . Current studies have shown that Cdh1 is a critical E3 ligase that targets SKP2 for ubiquitylation and degradation (17, 18) . However, the molecular mechanisms underlying elevated SKP2 expression have not been fully explored.
In the present study, we found that PKCι promoted ESCC cell migration, invasion, resistance to anoikis, growth in soft agar in vitro and tumor growth and lung metastasis in vivo.
Mechanistically, we showed that PKCι promoted resistance to anoikis through the SKP2-PI3K/AKT pathway and that PKCι regulated the expression of anoikis-related SKP2 via the ubiquitin-proteasome pathway.
Materials and methods

Tissue Specimens
Fresh tissues containing ESCCs and adjacent histologically normal epithelia were procured from surgical resection specimens collected by the Department of Pathology in the Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China. Primary tumor regions and histologically normal esophageal mucosa from the same patients were separated by experienced pathologists and immediately stored at -70 ℃ until use. No treatment was received by any patients before surgery, and all patients signed separate informed consent forms for sample collection.
Plasmid construction and small interfering RNA synthesis
The full-length coding regions of human PKCι and SKP2 were amplified from total cDNA and a non-silencing siRNA (5'-TTCTCCGAACGTGTCACGT-3') were chemically synthesized (GeneChem, Shanghai) for transient transfection. A PKCι RNAi construct was obtained by introducing double-stranded oligonucleotides that were synthesized according to siRNA-2 into the PGCsi.U6.neo.GFP shRNA expression vector (GeneChem).
Cell culture and transfection
The human cell line EC9706 was established in our laboratory (21 incubator, the insert was washed with PBS, and cells on the top surface of the insert were removed by wiping with a cotton swab. For the Matrigel chemoinvasion assay, the procedure was similar to the haptotactic cell migration assay, except that the Transwell membrane was coated with 300 ng/μL Matrigel (BD Biosciences, San Jose, CA), and the cells were incubated for 36 h at 37 ℃. Cells that migrated to the bottom surface of the insert were fixed with methanol, stained with 0.4% crystal violet and subjected to microscopic inspection. Cells were counted based on random five field digital images at ×200.
Adhesion assay
PKCι siRNA cells, non-silencing siRNA cells, and parental EC9706 cells were plated on 100 ng/μL Matrigel-coated 96-well plates at a density of 5×10 4 per well. The cells were incubated at 37 ℃ for 20, 40, 60, and 90 minutes, respectively, in a CO 2 incubator.
Nonattached cells were removed by three washings with PBS. Attached cells were analyzed
-tetrazolium (MTS; Promega, Madison, WI) assay, according to the user's manual.
Assessment of anoikis and treatment of inhibitor
Cells were cultured in dishes coated with PolyHEMA (Sigma), as described previously (22) .
Six-well polyHEMA plates were made by applying 1.5 ml of a 10 mg/ml solution of 
Soft agar assay for colony formation
Colony formation assay in soft agar was based on a modified method (23) . Cells transfected with PKCι RNAi or scramble sequence RNAi were plated in 6-well plates at a density of 500 cells per well. Three independent wells were examined per clone. The cells were incubated at 37 ℃ in 5% CO 2 . After three weeks in culture, colonies were stained with 0.2% p-iodonitrotetrazolium violet (Sigma) and counted.
Xenograft assays in nude mice
Four six-week-old female athymic nu/nu nude mice (Vital River, Beijing) were chosen for in vivo analysis. Mixtures of stably transfected P4 and P8 or S1 and S2 clones were injected into nude mice. For each group, six mice were injected subcutaneously (s. 
In Vivo Ubiquitination Assay
Cells on 10-cm plates were transfected with PKCι siRNA-1 or non-silencing siRNA. After being transiently transfected for 24 h, cells were trypsinized, plated onto polyHEMA plates and treated with MG132 for 24 h. Then cells from each plate were collected into two aliquots.
One aliquot (three milligrams of cell lysate) was used for each immunoprecipitation reaction with 5 μg SKP2 antibody. Immunocomplexes were pulled down as described previously (24), resolved by SDS-PAGE and immunoblotted for the presence of the polyubiquitin-SKP2
protein complex using anti-ubiquitin antibody. Another aliquot was used for conventional Western blotting to confirm PKCι expression knockdown and for a loading control.
Tissue Microarray and Immunohistochemical Staining
A total of 133 formalin-fixed, paraffin-embedded ESCCs and corresponding normal epithelia were placed on the tissue microarray. For each case, normal tissues were repeated (9, 16) .
Statistical analysis
The differences in results between groups were compared using ANOVA or Student's t-test.
Data were expressed as mean±SD. The correlation between PKCι and SKP2 expression levels was analyzed using the Spearman correlation test. All statistical analyses were performed with the SPSS 13.0 Statistical program for Windows. P values < 0.05 were considered significant.
Results
RNAi of PKCι in EC9706 cells
EC9706 cells were used to explore the role of PKCι in ESCC in the current study because they are an ESCC cell line with PKCι overexpression (data not shown) and high metastatic ability. Two duplex PKCι siRNAs, targeting sequences in the 3'UTR and the coding region of the PKCι gene, respectively, PKCι siRNA-1 and siRNA-2, were chemically synthesized for transient down-regulation of PKCι expression. After transient transfection for 48 h, Western blot analysis showed that PKCι siRNA-1 and siRNA-2 could both effectively suppress the expression of PKCι (Fig. 1B) . Double-stranded oligonucleotides, synthesized according to PKCι siRNA-2, were inserted into PGCsi.U6.neo.GFP shRNA expression vectors. As shown in Fig. 3A , PKCι expression was suppressed in P4 and P8 clones. In this study, we refer to PKCι stably down-regulation clones as PKCι RNAi. Parallel experiments were performed using the scramble sequence RNAi clones (S1 and S2). Stably transfected clones were used for in vivo assays and colony-formation assays. 
PKCι depletion decreased the motility of ESCC cells
Our previous results showed that elevated expression of PKCι was correlated with lymph node metastasis in ESCC (9) . Metastasis is a complicated procedure that involves many steps.
Migration, invasion, and adhesion are all key components of metastasis, so we examined whether PKCι is involved in these stages. Haptotactic cell migration assays showed that after PKCι depletion, fewer cells migrated to the bottom of the chamber, compared to non-silencing and parental cells (Fig. 1A upper panel and 1C) . The invasive potential of the PKCι siRNA cells, as assessed by measuring the ability of cells to transverse a reconstituted basement membrane of Matrigel, was reduced when compared to that of the control cells (Fig.   1A lower panel and 1C) . Western blot analysis confirmed the suppression of PKCι expression in PKCι siRNA-transfected cells (Fig. 1B) . These experiments were repeated three times with similar results.
Because the PKCι-induced increase in migration could be the result of an increase in the adhesion of tumor cells to the substrate, we evaluated the adhesive abilities of three groups of cells by measuring the number of cells attached to Matrigel. No significant differences were detected by MTS assays among the groups (Supplementary Fig. S1 ). Thus, knockdown of PKCι expression drastically suppressed the mobility of EC9706 cells in vitro.
PKCι knockdown promoted cell anoikis via inactivation of the PI3K/AKT pathway
We subsequently analyzed whether PKCι expression affected cell cycle progression or apoptosis. Flow cytometric results showed that PKCι down-regulation had no effect on these phenotypes ( Supplementary Fig. S2 and S3 (9) and anoikis is one type of apoptosis involved in tumor metastasis (25) . The percentage of PKCι siRNA apoptotic cells was approximately two-fold higher than the control and parental cells by Annexin V-FITC/propidium iodide staining (Fig. 2B, C) . To confirm that the results of the siRNA experiments described above were due to the inhibition of PKCι expression, we expressed human PKCι as a transgene in PKCι siRNA cells. In this experiment, PKCι siRNA-1 was used to knock down PKCι expression because it targets the 3'UTR of endogenous human PKCι mRNA, which makes it possible to reconstitute PKCι expression in PKCι siRNA-1 cells using an exogenous human PKCι expression construct that lacks the 3'UTR targeting sequence. When a plasmid encoding the PKCι gene was transfected into PKCι siRNA-1 cells, re-expression of PKCι rescued the ability of PKCι siRNA-1 cells to inhibit anoikis (Fig. 2E, F, G) , demonstrating a specific requirement for PKCι in the anoikis-resistance of EC9706 cells.
Molecular mechanisms of anoikis resistance have been described concerning several signaling pathways in different cell types. Our previous studies indicated that PI3K/AKT and MEK/Erk are two critical pathways mediating the anoikis of ESCC cells (16, 26, 27) . In this study, we examined the potential effects of PKCι on the activation of PI3K/AKT and MEK/Erk pathways. After PKCι depletion and cell suspension, p-AKT expression was down-regulated (Fig. 2D) , and no significant differences in p-Erk expression were observed in the three groups. Furthermore, p-AKT expression was suppressed no matter whether PKCι silenced cells were attached, detached or re-plated (Fig. 5C, D, E 
Knockdown of PKCι inhibited colony formation of ESCC cells in soft agar and s.c. tumor growth in nude mice
To investigate the effect of PKCι expression on tumor growth, we examined in vitro cell growth rate using MTS cell proliferation assays. No significant changes in growth rate were observed between PKCι RNAi and scramble sequence RNAi cells (Fig. 3B) . By contrast, depletion of PKCι significantly blocked the ability of EC9706 cells to grow as anchorage-independent colonies in soft agar (Fig. 3C, D) . Tumor formation assays in nude mice were performed to investigate the effect of PKCι expression on tumor growth in vivo. (Fig. 3G) .
PKCι inhibition decreased lung metastases in nude mice
Given that increased cell migration and suppression of anoikis both contribute to the metastatic potential of cancer cells, we tested whether inhibition of PKCι would affect the ability of EC9706 cells to metastasize. PKCι RNAi and scramble sequence RNAi cells were introduced via tail vein into eight nude mice from each group. Eleven weeks after injection, the animals were sacrificed and examined for the presence of lung metastases. In the scramble sequence RNAi group, two mice developed visually observable lung nodules and another two 
PKCι regulated resistance to anoikis through SKP2
Our previous study suggested that SKP2 was also implicated in PI3K/AKT-mediated anoikis resistance in EC9706 cells (16) . Therefore, we hypothesized that there may be a regulating relationship between SKP2 and PKCι. Western blot analysis in this study indicated that SKP2 expression did not change in adherent cells after PKCι knockdown (Fig. 5A ) but was markedly decreased in detached cells (Fig. 5B) . To verify that PKCι directly controlled These data revealed a novel required role for PKCι-SKP2 signaling in ESCC cells anoikis-resistance (Fig. 5F, G) . (Fig. 6A) . To further support these results, immunoprecipitation experiments with anti-SKP2 antibody were utilized, followed by immunoblotting with anti-ubiquitin antibody. In the presence of MG132, the ubiquitin was observed in the SKP2 immunocomplex, and its amount was substantially increased in the PKCι knockdown group (Fig. 6B, upper panel) . Western blot analysis ( 
PKCι regulated SKP2 protein expression through the ubiquitin-proteasome pathway
Correlation between PKCι and SKP2 expression in ESCC tissues
To determine the relationship between PKCι and SKP2 in tumor tissues, we analyzed their protein expression using an immunohistochemical approach combined with tissue microarray.
Immunohistochemistry results showed that of 133 specimens tested, all normal epithelia had 
negative or weak PKCι and SKP2 expression, whereas 50 (37.6%) of the tumors had more intense staining of PKCι, and 40 (30.1%) exhibited high SKP2 expression than normal tissues.
PKCι expression was significantly correlated with SKP2 expression in the tumors (P = 0.031, Table 1 and Fig. 7) .
Discussion
We previously reported that both frequent amplification and overexpression of PKCι were associated with lymph node metastasis in ESCC, suggesting that PKCι might play a key role in the progression of the disease (9) . To evaluate this possibility, we first assessed PKCι protein expression in a panel of ESCC cell lines. We chose EC9706 cells for the PKCι functional studies because they were shown to have high PKCι expression (data not shown) and are frequently used in ESCC metastasis research (16, 26, 27) . 
cells survive in an anchorage-independent manner, leading to metastasis in ESCC patients.
Molecular mechanisms of anoikis resistance have been described concerning several signaling pathways in different cell types. Our previous studies indicated that PI3K/AKT and MEK/Erk are two critical pathways mediating the anoikis of ESCC cells (16, 26, 27) . We revealed that after PKCι inhibition, AKT phosphorylation was decreased, whereas no difference in Erk activation was observed. Moreover, re-expression of PKCι could activate AKT phosphorylation. These data indicated that PI3K/AKT signaling was the main downstream target responsible for the protective effect of PKCι against anoikis in ESCC cells.
Interestingly, our recent investigation revealed that SKP2 was also implicated in PI3K/AKT-mediated anoikis resistance in ESCC cells (16) . We therefore tested the hypothesis that SKP2 may participate in PKCι-associated anti-anoikis signaling pathways. Our data Cdh1 has been revealed as an E3 ligase that promotes SKP2 destruction (17, 18) . Several studies have reported on the relationship between the PI3K/AKT pathway and SKP2 (28) (29) (30) .
It has been observed that in 293T cells AKT1 phosphorylates SKP2 at Ser 72, which is required to disrupt the interaction between Cdh1 and SKP2, and as a result prevents SKP2 degradation by the APC-Cdh1 ubiquitin ligase complex (35, 36) . In the present study, we found that PKCι could activate AKT phosphorylation. Based on previous reports and our data, with SKP2 ( Supplementary Fig. S4B ). Our previous study found that decreased SKP2 reduced p-AKT expression and that the PI3K/AKT pathway is the downstream target of SKP2 (16) . Our previous and current data showed that SKP2 acts upstream of AKT, and PKCι might regulate SKP2 protein degradation through other molecules but not PI3K/AKT pathway.
Moreover, Mao et al. co-transfected breast cancer BT-549 cells with expression constructs encoding V5-tagged PKCλ/ι and HA-tagged AKT and then assessed co-immunoprecipitation of the transfected PKCλ/ι with AKT. They observed that exogenous PKCλ/ι was present at low level in AKT immunoprecipitates, indicating that PKCλ/ι interacts with AKT in breast cancer cells (37) . We did not observe PKCι, AKT1 and SKP2 co-precipitation in detached EC9706 cells in the present study ( Supplementary Fig. S4A ). These differential observations in our and other experiments might reflect that there exist distinct signaling networks in different cell lines. The detailed mechanism underlying PKCι regulation of SKP2 through the ubiquitin-proteasome pathway remains to be elucidated. Interestingly, we found that the addition of LY294002 also resulted in a decrease in PKCι protein level, indicating a possible negative feedback loop between PI3K/AKT and PKCι that may help to maintain the balance between cell survival and apoptosis.
In conclusion, our results provide evidence that PKCι promotes tumor metastasis through increased cell migration ability and anoikis resistance in ESCC. PKCι enhances resistance to anoikis via the PKCι-SKP2-AKT pathway. The data suggest that PKCι is a candidate oncogene involved in the progression of ESCC and that SKP2 is a downstream effector of PKCι signaling in ESCC. 
